Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

ISOPAQUE 440

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

Standard Dose
0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ISOPAQUE 440 is listed in Drugs@FDA under application 016847 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM Form and strength INJECTABLE;INJECTION - 0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML Sponsor GE HEALTHCARE Submission history Latest submission status date: 1979-02-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview ISOPAQUE 440 is listed in Drugs@FDA under application 016847 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM Form and strength INJECTABLE;INJECTION - 0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML Sponsor GE HEALTHCARE Submission history Latest submission status date: 1979-02-15 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.